ArticleJHLT open2025
Impella 5.5 use in women: A multicenter study.
Article in JHLT open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Impella 5.5 Support in Severe Cardiogenic Shock: Outcomes From the First Spanish Multicentre Cohort in Heart Transplant Centres.Interdisciplinary cardiovascular and thoracic surgery · 2026Observational
- Anticoagulation with bivalirudin is associated with improved biocompatibility in patients supported on microaxial flow pumps.JTCVS open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We sought to compare the outcomes of Impella 5.5 use between sexes. Methods: All adult patients who underwent Impella 5.5 implantation at the University of Pennsylvania and Columbia University between June 2020 and May 2024 were retrospectively reviewed. Demographics, baseline status, complications, and outcomes were compared between sexes. Laboratory values were examined with a linear mixed model, and a parsimonious multivariable logistic regression was developed to assess factors predictive of in-hospital mortality. Results: Of 254 patients, 41 (16%) were female and 213 (84%) were male. Before implant, females had lower hemoglobin levels (9.6 vs 11.2 g/dl, Conclusions: Females do not experience increased complications from the Impella 5.5, nor reduced device biocompatibility. Our data support greater consideration of device use in females.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.